Genzyme, Daiichi Sue Watson Over Generic Welchol

Law360, New York (April 19, 2011, 3:39 PM EDT) -- Genzyme Corp. and Daiichi Sankyo Co. Ltd. launched a patent infringement suit Monday in Delaware federal court over Watson Pharmaceuticals Inc.’s efforts to produce a generic version of the cholesterol drug Welchol.

Genzyme and Daiichi allege that Watson’s abbreviated new drug application to produce a 625-milligram colesevelam hydrochloride tablet would infringe two patents owned by Genzyme and exclusively licensed by Daiichi for use in the U.S.

"Plaintiffs will be irreparably harmed by Watson’s infringing activities unless those activities are enjoined by this court," the complaint said....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.